Helmuth van Es
Fondateur chez Antabio SAS
Profil
Helmuth van Es is the founder of Galapagos NV, which was founded in 1999.
He is also the founder of Antabio SAS, which was founded in 2009, where he holds the title of Director.
Additionally, Dr. van Es was the founder of Citryll BV, which was founded in 2015, where he held the title of Chief Executive Officer until 2023.
Dr. van Es is also the founder of Audion Therapeutics BV.
After his founding positions, Dr. van Es held a former job as a Member-Advisory Board at Spinnovation Holding BV.
Postes actifs de Helmuth van Es
| Sociétés | Poste | Début |
|---|---|---|
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Fondateur | 08/10/2009 |
Audion Therapeutics BV
 Audion Therapeutics BV Pharmaceuticals: MajorHealth Technology Audion Therapeutics BV is a biopharmaceutical firm. It specializes in the discovery, development, and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. The company was founded by Rolf Jan Rutten, Albert Edge, and Helmuth van Es and is headquartered in Amsterdam, the Netherlands. | Fondateur | - |
Anciens postes connus de Helmuth van Es
| Sociétés | Poste | Fin |
|---|---|---|
Citryll BV
 Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Directeur Général | 01/03/2023 |
Spinnovation Holding BV
 Spinnovation Holding BV Medical/Nursing ServicesHealth Services Spinnovation Holding BV operates as a holding company with interests in solving problems in material, chemical, and biological sciences via a unique combination of NMR spectroscopic methods. The firm provides access to a high-tech NMR platform based on spectrometers ranging from 300 MHz to 800 MHz. The company was founded in 2004 and is headquartered in Nijmegen, the Netherlands. | Corporate Officer/Principal | - |
| GALAPAGOS NV | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GALAPAGOS NV | Health Technology |
| Entreprise privées | 4 |
|---|---|
Audion Therapeutics BV
Audion Therapeutics BV Pharmaceuticals: MajorHealth Technology Audion Therapeutics BV is a biopharmaceutical firm. It specializes in the discovery, development, and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. The company was founded by Rolf Jan Rutten, Albert Edge, and Helmuth van Es and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Spinnovation Holding BV
Spinnovation Holding BV Medical/Nursing ServicesHealth Services Spinnovation Holding BV operates as a holding company with interests in solving problems in material, chemical, and biological sciences via a unique combination of NMR spectroscopic methods. The firm provides access to a high-tech NMR platform based on spectrometers ranging from 300 MHz to 800 MHz. The company was founded in 2004 and is headquartered in Nijmegen, the Netherlands. | Health Services |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Health Technology |
Citryll BV
Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Commercial Services |
